Lazard Capital Analysts Downgrade NuPathe Inc (PATH) Shares to "Neutral"
Wednesday, August 31, 2021 9:35 AM



Equities research analysts at Lazard Capital downgraded shares of NuPathe Inc (NASDAQ: PATH) from a "buy" rating to a "neutral" rating in a research note to investors on Wednesday.

Separately, analysts at Needham & Company downgraded shares of NuPathe Inc from a "buy" rating to a "hold" rating in a research note to investors on Tuesday. Also, analysts at Wedbush cut their price target on shares of NuPathe Inc from $20.00 to $17.00 in a research note to investors on Tuesday. They now have an "outperform" rating on the stock.

Shares of NuPathe Inc opened at 2.65 on Thursday. NuPathe Inc has a 52 week low of $2.06 and a 52 week high of $9.74. The stock's 50-day moving average is $5. and its 200-day moving average is $7.11. The company has a market cap of $39.1 million.

NuPathe Inc. (NuPathe) is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company’s product candidate, Zelrix, is a single-use patch applied to the arm or thigh for the treatment of migraine. Zelrix delivers sumatriptan through the skin in a controlled manner using its SmartRelief technology. Sumatriptan is available in oral, nasal and injectable formulations. The Company has two product candidates in preclinical development, which includes NP201 and NP202.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.


 

Sponsors

Advertisement


Advertisement